Lv11
60 积分 2025-10-15 加入
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
9小时前
已完结
Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study
2天前
已完结
Crohn's disease
2天前
已完结
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial
10天前
已完结
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials
10天前
已完结
Systematic Evaluation of Dose Accumulation Studies in Clinical Pharmacokinetics
15天前
已完结
皖公网安备34019202002308
